The Most Comprehensive Coverage of China’s Evolving Biologics Market
________________________________________
20 Case Studies ● Keynote from China SFDA Official
17 New Data Presentations ● Panel Discussions on Biosimilar and Analytical Methods
• Harness novel cell line technologies and approaches for improved developability and upstream processing
• Enhance analytical capabilities with new characterization and specification methods
• Benchmark your biosimilar program with case studies and new data on development and production
• Meet complex drug product and manufacturing challenges with new facility technologies and designs
http://www.ibclifesciences.com/bpichina
Why you should attend:
1. Learn from in-depth case studies on strategic partnering and effective collaboration
2. Explore new business opportunities and strategies to reach the biosimilars market in the region
3. Gain insights into the regulatory landscape for biosimilars in China, India, Korea, Taiwan and more
4. Gather the latest market intelligence and analysis and identify new trends and opportunities in Biosimilars R&D, contract manufacturing and commercialization in Asia
报名参加的五大理由
1. 深入学习有关与亚洲公司建立战略合作和有效协作的案例研究
2. 探索新的商机和战略,以便进入当地的生物仿制药市场
3. 深入了解中国、印度、韩国、台湾以及更多国家或地区的生物仿制药监管形势
4. 收集最新的市场情报和分析,确定生物仿制药研发、合同制造和商业化在亚洲的新趋势和机会
Hear about:
Biopharma Regulatory Updates and Development
Victoria Elegant, VP Medical & Regulatory Affairs, Baxter, China
Andrea Laslop, Head of Scientific Office, Austrian Agency for Food and Health Safety, Austrian Member, European Medicines Agency
Arvind Mishra, Global Head of Quality & Regulatory & Head of Strategic Business Unit, Biologicals, Cadilla Pharmaceutical, India
Advances in Biosimilars R&D
Jeffrey Su, CSO, Cytovance Biologics, USA
Wenzhi Tian, CEO, Huabo Biopharma, China
Ming Wang, President and COO, Gan & Lee Pharmaceuticals, China
Feng Li, CEO, Beijing Mabworks, China
Shaligram Rane, Vice President for Quality, Intas Pharmaceuticals, India
Understanding Obstacles and Hurdles for Entering the Biosimilars Market
Khai Meng Ang, Vice President Asia, Hospira, China
Jason Li, Senior Director, Genor Biopharma, China
Sachidananda Moorthy, Vice President - Clinical Research, Medical and Regulatory Affairs, Avesthagen, India
Sameer Agarwal, Senior Vice President, Business Center Strategic Marketing, Business Unit Generic Drugs & Standard Solutions, Fresenius Kabi, Germany
What can Asia Learn from Global Biosimilars Development and Litigation?
Li Cai, Regional R&D Counsel, Pfizer, China
Vivek Mittal, Head – Legal, Lupin, India
Viren Mahurkar, Managing Director, HitechnRock Advisors, Singapore
http://www.biosimilarsasia.com
Pre-Conference Special Focus Day, 20 May 2014
Clinical Development for Biosimilars
Post-Conference Workshops, 23 May 2014
A: Challenges in Demonstrating Biosimilarity and Interchangeability of Biosimilar Products
B: Successfully Bringing Biosimilars to Market
会前特别关注日,2014 年 5 月 20 日
生物仿制药的临床开发
会后研讨会,2014 年 5 月 23 日
A:在展示生物仿制药产品的生物相似性和可互换性方面所面临的挑战
B:成功地将生物仿制药推向市场
Why you should attend:
1. Learn from in-depth case studies on strategic partnering and effective collaboration
2. Explore new business opportunities and strategies to reach the biosimilars market in the region
3. Gain insights into the regulatory landscape for biosimilars in China, India, Korea, Taiwan and more
4. Gather the latest market intelligence and analysis and identify new trends and opportunities in Biosimilars R&D, contract manufacturing and commercialization in Asia
报名参加的五大理由
1. 深入学习有关与亚洲公司建立战略合作和有效协作的案例研究
2. 探索新的商机和战略,以便进入当地的生物仿制药市场
3. 深入了解中国、印度、韩国、台湾以及更多国家或地区的生物仿制药监管形势
4. 收集最新的市场情报和分析,确定生物仿制药研发、合同制造和商业化在亚洲的新趋势和机会
Hear about:
Biopharma Regulatory Updates and Development
Victoria Elegant, VP Medical & Regulatory Affairs, Baxter, China
Andrea Laslop, Head of Scientific Office, Austrian Agency for Food and Health Safety, Austrian Member, European Medicines Agency
Arvind Mishra, Global Head of Quality & Regulatory & Head of Strategic Business Unit, Biologicals, Cadilla Pharmaceutical, India
Advances in Biosimilars R&D
Jeffrey Su, CSO, Cytovance Biologics, USA
Wenzhi Tian, CEO, Huabo Biopharma, China
Ming Wang, President and COO, Gan & Lee Pharmaceuticals, China
Feng Li, CEO, Beijing Mabworks, China
Shaligram Rane, Vice President for Quality, Intas Pharmaceuticals, India
Understanding Obstacles and Hurdles for Entering the Biosimilars Market
Khai Meng Ang, Vice President Asia, Hospira, China
Jason Li, Senior Director, Genor Biopharma, China
Sachidananda Moorthy, Vice President - Clinical Research, Medical and Regulatory Affairs, Avesthagen, India
Sameer Agarwal, Senior Vice President, Business Center Strategic Marketing, Business Unit Generic Drugs & Standard Solutions, Fresenius Kabi, Germany
What can Asia Learn from Global Biosimilars Development and Litigation?
Li Cai, Regional R&D Counsel, Pfizer, China
Vivek Mittal, Head – Legal, Lupin, India
Viren Mahurkar, Managing Director, HitechnRock Advisors, Singapore
http://www.biosimilarsasia.com
Pre-Conference Special Focus Day, 20 May 2014
Clinical Development for Biosimilars
Post-Conference Workshops, 23 May 2014
A: Challenges in Demonstrating Biosimilarity and Interchangeability of Biosimilar Products
B: Successfully Bringing Biosimilars to Market
会前特别关注日,2014 年 5 月 20 日
生物仿制药的临床开发
会后研讨会,2014 年 5 月 23 日
A:在展示生物仿制药产品的生物相似性和可互换性方面所面临的挑战
B:成功地将生物仿制药推向市场
Factors to keep in mind when you’re considering cloud storage services.Rita Barry
Cloud storage is a broad term. It can encompass anything from on premise solutions, to le storage, disaster recovery and off premise options. To narrow the scope, I’ve dedicated the focus of today’s discussion to the more popular cloud storage services—such as Dropbox, Box, OneDrive—which are also known as hosted, off premise solutions.
Factors to keep in mind when you’re considering cloud storage services.Rita Barry
Cloud storage is a broad term. It can encompass anything from on premise solutions, to le storage, disaster recovery and off premise options. To narrow the scope, I’ve dedicated the focus of today’s discussion to the more popular cloud storage services—such as Dropbox, Box, OneDrive—which are also known as hosted, off premise solutions.
Unlike more tangible technologies where a failed implementation causes a down network, SIEM (security information and event management) requires a more qualitative approach to determining success or failure. The surprising reality is that most SIEM projects completely fail to deliver any discernable bene ts to the organization and are abandoned in frustration
www.rkon.com
Carve-outs and Mergers and Acquisitions place unique demands on IT. How can y...Rita Barry
Mergers are complex and Carve-outs only add to the dif culty and the level of complexity that the delivery team must manage. The creation of a stand-alone entity in a matter of weeks is daunting; moreover, the lack of cooperation from the legacy organization or the attrition of employees creates a chaotic environment that must be overcome. RKON helps clients to determine the most favorable level of IT sourcing and to implement the most appropriate technology for the new business unit — all to ensure a successful “day one.”
Tertiary Hospital Services Asia 2015, part of the Asia Healthcare Summit, will examine successful case studies on achieving top financially performing healthcare organizations whilst delivering quality tertiary healthcare services.
Top Industry Issues to Be Discussed Include:
Benchmarks and lessons from World Class Tertiary Hospitals
Insights on clinical and operational excellence
Investment in Tertiary Hospital Services and achieving financial success
Streamlining outpatient services
Advanced consultative care & remote monitoring of patient health
Latest technology transforming patient accessibility, care and experiences
Keynote representatives and decision makers from more than 15 public and private hospitals across the Asia Pacific region will convene and share their perspectives in developing world class tertiary hospital services, including:
Chan Choo Lin, Director of Operations, Johns Hopkins, Singapore
Dr. Alejandro C. Dizon, Chief Quality Officer, St. Luke's Medical Center, Philippines
Alastair Mah, Chief Medical Officer, University Hospital Geelong & Barwon Health, Australia
Haji Abdul Aziz Abdul Rahman, CEO, KPJ Penang Specialist Hospital, Malaysia
Seemant Jauhari, CEO, Research & Innovations, Apollo Hospitals, India
Nguyen Thi Le Thu, Marketing & Business Development Director, FV Hospital, Vietnam
Grace Siew Wah Lim, Chief Financial Officer, KK Woman’s and Children’s Hospital, Singapore
Andres M.Licaros, Jr., President & Chief Executive Officer, Asian Hospital and Medical Center, Philippines
Michael Wong, CEO, Pantai Hospitals (Ayer Keroh), Malaysia
David Sun, Consultant of Neurosurgery, Prince of Wales Hospital, Hong Kong
Joe Hau, Director Corporate Services, Tan Tock Seng Hospital, Singapore
Alan Young, Head of IT, Canossa Hospital (Caritas), Hong Kong
Prof Kazuhiro Hara, President, Japanese Telemedicine and Telecare Association, Specially-appointed professor of Seto Inland Sea Regional Research Center, Kagawa University, Japan
Chan Woo Kuk, Center for Future Innovation, Advisory Specialist, Samsung Medical Center, Korea
http://www.tertiaryhospitalservices.com
Biopharma Production & Development Week 2015 Rita Barry
What’s New for 2015
- C-Level Panel: Cutting Edge Insights on China’s Growing Biotech Market
- China FDA Special Address
- 80+ Key Expert Speakers from Asia’s leading Pharma & Biotech
- 1 Joint Exhibition & Networking Area
- 4 Days of Expert Knowledge Sharing
- Revamped Program with New Special Focused Tracks & Sessions
Cell Line Development and Engineering 2015 Rita Barry
The 4th Annual Cell Line Development & Engineering Asia conference is a must attend event for you to get the latest updates and best practices in Cell Line Generation, Bioprocessing and Antibodies Development!
This exclusive forum is where industry experts will share lessons learned through case studies, strategic discussion groups and interactive roundtables to collectively collaborate and provide solutions to your most pressing challenges. Bring back new ideas to do better business!
4 Reasons Why You Must Attend this 2015
1. Update yourself with latest technologies to accelerate every stage of cell line development with maximum efficiency, quality and reduced cost
2. Enhance cell line generation in the early stages with best practices in transfection, optimizing cell culture media, and implement advancements in clone screening and selection techniques
3. Gain effective bioprocess control & optimization strategies, for efficient, safe and cost effective scale-up
4. Latest cutting edge updates on antibody development- novel screening strategies for target discovery, challenges in ADCs, engineering bispecifics and boosting efficacy in antibody therapeutics
http://www.celllineasia.com
What’s NEW in 2015’s program?
• More case studies on successful commercialization
• Insights on developing biosimilars under new CFDA guideline
• Emerging business models in regulated and developing markets
• New and timely topics on:
o Valuating biosimilars investments
o Successful technology transfer
o Key criteria in gaining approval
Also, NEW Expert Faculty includes:
Dr Shin Jae Chang, Vice President, Celltrion, Korea
Ira Jacobs, Global Oncology Lead, Biosimilars, Pfizer, US
Paul Thomas, Business Unit Head – Biosimilars, Biocon, India
Dr. Martina A. Sersch, Global Clinical Lead, Oncology Global Development, APAC Biotherapeutics Lead, Genentech, Inc. / F. Hoffmann-La Roche Ltd.
Raj Kannan, Vice President, Commercial Head, Biosimilars, Merck, Switzerland
Huiguo (Forrest) Hu, General Manager of International Business, Shanghai CP Guojian Pharmaceutical Co., Ltd, China
Ko Chung Lin, Chief Executive Officer, PharmaEssentia Corporation, Taiwan
Wen Yong, Vice Director, Drug Research Institutes, Biopharmaceutical Institute, Jiangsu AoSaiKang Pharmaceutical Co Ltd, China
http://www.biosimilarsasia.com
“A key source of growth in biologics over the next several years will be Biomanufacturing” Ge Li, Chairman and CEO, Wuxi” <outsourcing-pharma.com,>
“Other issues with single-use include standardization of systems, the dependability to vendors, and the supply chain and waste management but if we can overcome extractables and leachables, we will eventually be able to scale up to many thousands of liters.” Jason Li, Senior Director, Downstream Processing, Genor Biopharma <biopharma-reporter.com,>
Industry experts will discuss these and more at the 5th Annual Biomanufacturing Conference in Grand Hyatt Shanghai, China on 19 – 22 May 2015 during IBC’s Biopharma Development & Production (BDP) Week.
As you know, pharma compliance is a critical issue, particularly in China. The Chinese government’s recent crackdowns on the business practices of various pharmaceutical companies have sent shockwaves throughout the industry and the price to pay for non-compliance is exceedingly high, with massive revenue losses and irreclaimable reputational damages
To address this pertinent issue, IBC Asia is convening the forthcoming Pharma Compliance Summit
(Mar 2015) in Shanghai, China. Set to be an informative and insightful event, this conference will prepare participants in dealing with the latest legal compliance landmines and equip them with an in-depth understanding of how to mitigate non- compliance risks at every part of the pharma value chain.
Top companies will share best practices of internal compliance programs and third party due diligence strategies; Gain these exclusive insights and incorporate them into their own company, reaping maximum benefits.
Your expert speaker faculty includes:
• Leon Wang, Vice President, AstraZeneca China
• Heike Deters, Head of Compliance, Bayer Healthcare China
• Dr Wang Xianlin, Member, Expert Advisory Group of Anti-Monopoly Commission, State Council People’s Republic of China
• Maija Burtmanis, Regional Legal & Compliance Director JAPAC, AbbVie
• Gareth Lee, General Counsel & Head of Compliance APAC, Allergan
• Cristopher Landrito, Regional Compliance Manager APAC, Merck
• David Shen, General Counsel & VP Legal, AstraZeneca China
• Dr Wu Ke, President, Shanghai BravoBio
• Alejandro Castro, Regional Audit Manager Asia Pacific, Novartis
• Linda Ling, Senior Healthcare Compliance Manager, OTC China, Johnson & Johnson
http://www.pharmacompliance-china.com
IBC’s OTC Pharma Asia conference is returning 2-5 March 2015 at Grand Copthorne Waterfront Hotel, Singapore to prepare you for future growth in the OTC and Consumer Health market in Asia. You will witness how the OTC landscape varies by country as well as the latest product trends, consumer insights and innovative offerings in OTC – a crucial element to achieve global success.
http://www.otcpharmaasia.com
The inaugural Philippines Healthcare will focus on investment opportunities in the Philippines healthcare sector as well as examine the developments in healthcare plans and policies by government, market access opportunities for pharma and technology, new healthcare facility projects, upgrades and expansions and increasing efficiencies of existing facilities.
Philippines is currently focused on speeding up health facilities and upgrades, meeting the needs and growing demand for health specialists, training to ensure competency and quality of healthcare services and ensuring the availability of drugs throughout the country.
The conference will have discussions on policy and regulation updates, investment opportunities, projects and developments to strengthen Philippines healthcare infrastructure and delivery.
It will be held in Manila and will have representations from government, hospitals, insurance companies, pharma companies, health technology and medical device providers and other related stakeholders.
For 2015, we are going to hear NEW panel speakers from Indonesia Stock Exchange, Australia Stock Exchange, Philippine Stock Exchange, Tokyo Stock Exchange, Osaka Stock Exchange and Colombo Stock Exchange. Each of the exchanges will present a 10 minute update about their country on what are the new initiatives that have rolled out, how they address the needs of the private side, which infrastructure support the local regulatory body address in the short term vs. long term and the ASEAN trading link to ease cross border trading.
Not only that, we will answer key questions of the post trade industry including:
• Have Asian market participants been preparing for operational readiness as Dodd Frank, Emir and Basel 3 are being unrolled in Asia?
• Will T2S lead to a migration of all financial players to ISO 20022 in Europe?
• What are the impacts of Hong Kong Shanghai Stock Connect on Asia’s economy and the global financial markets?
• What is the impact on transaction funding and foreign exchange operations of moving from T+3 to T+2?
• Are CCPs all equal? Can we quantify the benefits of moving to a CCP?
• How is the buyside firm in Asia dealing with a collateral solution? Do the costs outweigh the benefits?
Biopharma Production and Development China 2015 Rita Barry
As the BioPharma industry grows in China and the Asian region, we invite you to be a part of this tremendous growth & development opportunities!
IBC’s Biopharma Development & Production Week in China is THE meeting place for biopharma industry professionals and scientists to get the highest quality and practical information that will enable them to develop competitive advantages and advance their capabilities in developing and manufacturing cell lines, biosimilars, biobetters, vaccines or novel biologics.
Top Reasons Why You Should Participate:
- Establish Business Partnerships with Chinese/Asian drug developers and contract
manufacturers
- Learn technical & practical know how from experiences on the ground in Asia
- Showcase your cutting edge solutions in front of key China/Asian Biopharma
decision makers
http://www.biopharmaproduction.com
With cancer being the fastest growing healthcare priority in the pharmaceutical industry, IBC Asia announces the region's first ever strategic oncology conference focusing on clinical development and market access.
Download the brochure <link> now to identify new trends and opportunities in development and commercialization in the region.
ONCOLOGY ASIA focuses on the clinical development and effective market access for cancer drugs in Asia. It will cover strategies for developing oncology products and businesses from innovative pipelines, commercializing products, sales and marketing strategies to capture opportunities in Asia’s markets.
Featured sessions from top industry thought leaders:
Market Trends and Drivers in the Region
• James Garner, Head Unit Development Operations, Asia R&D, Sanofi, Singapore
What You Need to Know When Marketing Oncology Drugs
• Dr Paul Cornes, Clinical Oncologist, Bristol Oncology Centre, UK
Successful Market Access Strategies for Oncology Drugs
• Sameer Agarwal, Senior Vice President, Business Center Strategic
Marketing, Fresenius Kabi Deutschland GmbH, Germany
Clinical Engagement for Successful Oncology Products
• Dr Anish Desai, Director Medical & Clinical Affairs, Johnson & Johnson, India
http://www.oncologyasia.com
The offshore RMB market has evolved rapidly since 2010 and there have been periods of significant pricing dislocation between onshore and offshore forex and interest rate markets. Over the medium to long term, as the RMB exchange rate becomes more flexible, more products are traded in the offshore RMB market with growing liquidity, and capital account is gradually liberalized, the convergence trend in the pricing of onshore and offshore RMB asset markets is inevitable. <China Money Network, 28 July 2014)
The Value of RMB Currency in the Market, Liquidity & Risk will be discussed at IBC’s Offshore RMB Seminar (Parkroyal on Beach Road, Singapore * 27 November 2014) by these industry leaders:
Joe Ng, Head of Renminbi Payments Product Management - Asia Pacific, Global Transaction Banking, Deutsche Bank, Hong Kong
Update Speaker from Gladys, ICBC, Singapore
Motasim Iqbal, Head of Transaction Banking, Standard Chartered Bank, Singapore
Noritaka Akamatsu, Deputy Head, Office of Regional Economic Integration, Chair, Financial Sector Community of Practice, Asian Development Bank, Philippines
Other Key Topics Addressed Include:
• RMB Policy Liberalization
• Investing in RMB Capital Markets
• RMB Cross-Border Settlements
• Developing of Offshore RMB Operations
View more at http://www.offshorermbseminar.com
A successful generic product starts with understanding consumer needs and brand value. On November 4-7 in Singapore, IBC will host the 9th Annual Generics Asia 2014, Asia’s longest running Generics conference, to help you and your organization understand how to incorporate marketing and partnership into your business strategy.
The key topics to be covered at the event include:
Regulatory Update and Accelerating Access to New market
o A panel of experts from Philippines Chamber of Pharmaceutical Industry, Actavis, Hovid and Pfizer
Building Brand Awareness and Delivering New Products with a Cost Effective Strategy
o Allan Marx Ancheta, Director Business Development and Strategy, Commercial Innovation and Alliance, Merck
Managing Sale Force Effectiveness and Innovative Channels for Generics Products
o Marvin Biliwang, Commercial Effectiveness Director, Takeda Pharmaceuticals
Establishing Partnerships to Add Value and Build Market Share
o Philip Cox, President Director, PT Takeda Indonesia
Innovative Models and Super Generics for Prolonging Product Life Cycles
o Dr. Shirish Kulkarni, Senior Vice President, Formulation Development, Sun Pharmaceutical
IBC’s Indonesia Healthcare conference brings together healthcare leaders to discuss evolving policies, opportunities for private healthcare investment, partnerships, projects and initiatives.
Key Conference Themes:
Updates on Regulation and the Road Towards Universal Healthcare Coverage
Hospital Management & Cutting Edge Healthcare Delivery Standards
Digital Marketing and Telehealth Solutions
Healthcare Infrastructure Projects, Investments & Development
Generics & Access to Medicine
Public-Private Partnerships & Collaboration
Why You Must Attend This Year’s Event
Understand the proactive steps to take by hospitals, pharmaceutical and insurance companies for the new Universal Healthcare Coverage policy
Discover partnerships and investment opportunities in Indonesia
Hear different case studies from major hospitals, insurance and pharmaceutical companies
Meet and exchange business cards with your peers during the networking sessions
Learn how to deliver safe and quality healthcare from other Asian countries